WuXi's Customer Focused Business Model Shows the Changing Relationship Between Drug Makers and CROs
Beset by the hurdlesand dynamics of drug discovery, service providers have evolved from traditional vendors performing non-core support to their pharma and biotech customers, to becoming critical partners. WuXi has adapted quickly to seize new opportunities.
You may also be interested in...
WuXi PharmaTech's spectacular public offering last summer piqued foreign investors' interest. Top tier VC firms are now investing in contract research organizations, manufacturing plays, and start-ups shifting business operations to China.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.